The company had posted a net profit of Rs 201.5 crore in the same period of the previous fiscal.
Net sales rose to Rs 970.3 crore for the fourth quarter, up 16.84 per cent, from Rs 830.4 crore a year ago, Biocon said in a BSE filing.
During the quarter under review, Biocon reported exceptional income of Rs 268.4 crore.
For the year to March 2016, net profit stood at Rs 896.1 crore compared with Rs 497.4 crore in 2014-15.
In a separate filing, Biocon also announced appointment of M Damodaran as additional independent director of the company.
The stock was trading up 1.32 per cent at Rs 571.75 on BSE at 1240 hours.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%